RECURRENT MULTIPLE MYELOMA

This early-phase trial tests whether adding an experimental drug called SX-682 to standard cancer drugs is safe for people with multiple myeloma that has come back or not responded to prior therapy. SX-682 works by blocking signals that suppress the immune system, potentially hel…

This study tests whether adding two drugs, dasatinib and quercetin, to standard CAR-T cell therapy can improve outcomes for people with multiple myeloma that has returned or not responded to prior treatments. About 44 adults who have tried at least three other therapies will rece…

This early-phase trial tests a combination of two drugs—iberdomide and teclistamab—in people with multiple myeloma that has come back or stopped responding to at least four prior treatments. The goal is to find the safest and most effective dose of iberdomide when used with tecli…

This study tests whether reducing the dose of the drug linvoseltamab, based on how well a patient responds early on, is safe and effective for people with multiple myeloma that has come back or stopped responding to other treatments. Linvoseltamab helps the immune system attack c…

This early-phase trial tests a new treatment for multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified in the lab with CRISPR gene editing to target and attack cancer cells. About 30 adults will …

This study is for people with multiple myeloma that has returned or not responded to at least three prior treatments. It tests different doses and schedules of a drug called belantamab mafodotin, which targets and kills cancer cells. The goal is to find a dose that controls the c…

This study tests whether adding a new drug (iberdomide) to an existing treatment (belantamab mafodotin plus dexamethasone) is safe and works better for multiple myeloma that has come back or stopped responding. About 88 adults with this blood cancer will receive either the new co…

This study tests a combination of four drugs (iberdomide, daratumumab, elotuzumab, and dexamethasone) in people whose multiple myeloma has returned after previous treatment. The goal is to find the safest dose and see how well the drugs work together to shrink or control the canc…

This study is testing a three-drug combination (MeziKD) for adults with multiple myeloma that has come back or stopped responding to other treatments and has spread to form tumors in soft tissues or organs. The goal is to see if this combination can shrink these tumors and contro…

This study tests whether a personalized exercise program (aerobic and resistance training) done before CAR-T therapy can improve physical fitness and quality of life in adults aged 60 and older with multiple myeloma that has returned or not responded to treatment. About 20 partic…